Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024 The collaboration supports Teva’s Pivot to Growth strategy and adds to the company’s biosimilar portfolio Both